Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Internal Medicine | Nephrology | Journal

Back to Journal Articles

Glycocalyx Barrier Impaired in Dialysis Patients

Last Updated: October 19, 2012.

 

Patients also have elevated serum levels of glycocalyx constituents and hyaluronidase activity

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Patients undergoing dialysis have an impaired glycocalyx barrier and elevated levels of its constituents in their blood, according to a study published online Oct. 18 in the Journal of the American Society of Nephrology.

FRIDAY, Oct. 19 (HealthDay News) -- Patients undergoing dialysis have an impaired glycocalyx barrier and elevated levels of its constituents in their blood, according to a study published online Oct. 18 in the Journal of the American Society of Nephrology.

Carmen A. Vlahu, M.D., from the Academic Medical Center in Amsterdam, and colleagues used Sidestream Darkfield imaging to detect changes in glycocalyx dimension in dialysis patients and healthy controls based on in vivo recordings of the sublingual microcirculation.

The researchers found that dialysis patients had increased perfused boundary region and perfused diameters, consistent with deeper penetration of erythrocytes into the glycocalyx. Dialysis patients also had elevated serum levels of the glycocalyx constituents hyaluronan and syndecan-1, as well as increased hyaluronidase activity. The imaging parameters were not influenced by loss of residual renal function, but there was an association with greater shedding of hyaluronan in blood. Higher levels of inflammation in patients correlated with more significant damage to the glycocalyx barrier.

"In conclusion, in this study, we show that dialysis patients have loss of glycocalyx barrier properties as estimated by analysis of the dynamic variations of erythrocyte column width in the sublingual microcirculation," the authors write. "Impaired glycocalyx barrier properties, together with shedding of its constituents into blood, are consistent with sustained pathogenic endothelial cell activation in dialysis patients and probably contribute to the aggressive vascular pathology present in this group of patients."

Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.


Previous: Prognostic Factors Identified for Intramedullary Tibial Nailing Next: Anergia Prevalent in Acute Coronary Syndrome Patients

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.